Abstract
Due to their role in cellular signaling mitogen activated protein (MAP) kinases represent targets of pharmaceutical interest. However, the majority of known MAP kinase inhibitors compete with cellular ATP and target an ATP binding pocket that is highly conserved in the 500 plus representatives of the human protein kinase family. Here we review progress toward the development of non-ATP competitive MAP kinase inhibitors for the extracellular signal regulated kinases (ERK1/2), the c-jun N-terminal kinases (JNK1/2/3) and the p38 MAPKs (α, β, γ, and δ). Special emphasis is placed on the role of computational methods in the drug discovery process for MAP kinases. Topics include recent advances in X-ray crystallography theory that improve the MAP kinase structures essential to structurebased drug discovery, the use of molecular dynamics to understand the conformational heterogeneity of the activation loop and inhibitors discovered by virtual screening. The impact of an advanced polarizable force field such as AMOEBA used in conjunction with sophisticated kinetic and thermodynamic simulation methods is also discussed.
Keywords: Kinases, MAP, modeling, dynamics, non-ATP, inhibitor
Current Pharmaceutical Design
Title: Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Volume: 18 Issue: 9
Author(s): Michael J. Schnieders, Tamer S. Kaoud, Chunli Yan, Kevin N. Dalby and Pengyu Ren
Affiliation:
Keywords: Kinases, MAP, modeling, dynamics, non-ATP, inhibitor
Abstract: Due to their role in cellular signaling mitogen activated protein (MAP) kinases represent targets of pharmaceutical interest. However, the majority of known MAP kinase inhibitors compete with cellular ATP and target an ATP binding pocket that is highly conserved in the 500 plus representatives of the human protein kinase family. Here we review progress toward the development of non-ATP competitive MAP kinase inhibitors for the extracellular signal regulated kinases (ERK1/2), the c-jun N-terminal kinases (JNK1/2/3) and the p38 MAPKs (α, β, γ, and δ). Special emphasis is placed on the role of computational methods in the drug discovery process for MAP kinases. Topics include recent advances in X-ray crystallography theory that improve the MAP kinase structures essential to structurebased drug discovery, the use of molecular dynamics to understand the conformational heterogeneity of the activation loop and inhibitors discovered by virtual screening. The impact of an advanced polarizable force field such as AMOEBA used in conjunction with sophisticated kinetic and thermodynamic simulation methods is also discussed.
Export Options
About this article
Cite this article as:
J. Schnieders Michael, S. Kaoud Tamer, Yan Chunli, N. Dalby Kevin and Ren Pengyu, Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases, Current Pharmaceutical Design 2012; 18 (9) . https://dx.doi.org/10.2174/138161212799436368
DOI https://dx.doi.org/10.2174/138161212799436368 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Poly(ADP-ribose)polymerase Inhibition - Where Now?
Current Medicinal Chemistry Reviewing Colchicaceae Alkaloids – Perspectives of Evolution on Medicinal Chemistry
Current Topics in Medicinal Chemistry Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Transcriptome and Proteome Analyses of Drug Interactions with Natural Products
Current Drug Metabolism Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Factors Controlling Chromatin Organization and Nucleosome Positioning for Establishment and Maintenance of HIV Latency
Current HIV Research Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa
Protein & Peptide Letters The Disulfide Analogues of Isophosphoramide Mustard for Anticancer Therapy
Letters in Drug Design & Discovery